Trial Profile

A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Bortezomib; Dexamethasone; Dexamethasone; Melphalan; Prednisone
Indications Multiple myeloma
Focus Registrational; Therapeutic Use
Acronyms ALCYONE
Sponsors Genmab; Janssen Biotech; Janssen Research & Development; Janssen-Cilag

08 Oct 2024 Status changed from active, no longer recruiting to completed.
01 Oct 2024 This trial has been completed in Poland according to European Clinical Trials Database record.
13 Sep 2024 This study has been Completed in Greece.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com